Analgesics

Tanezumab’s Phase 3 Results for OA

June 25, 2019 • By Michele B. Kaufman, PharmD, BCGP

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

May 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

Chronic Opioid Use in Rheumatoid Arthritis: Prevalence & Predictors

May 1, 2019 • By Arthritis & Rheumatology

Tips for Interdisciplinary Pain Management in Older Patients

April 15, 2019 • By Susan Bernstein

Clinicians’ Use of ‘Safer’ Opioid-Prescribing Practices Spotty

March 5, 2019 • By Anne Harding

Tanezumab for OA Pain

February 21, 2019 • By Michele B. Kaufman, PharmD, BCGP

Ibuprofen an Option for Early Pain Control after Hip Replacement

February 13, 2019 • By Reuters Staff

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

February 4, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones

January 23, 2019 • By Michele B. Kaufman, PharmD, BCGP

ah_designs / shutterstock.com

The Perils of Pain Meds Revisited

December 18, 2018 • By Stephen G. Gelfand, MD, FACP, FACR